Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633789 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Phase 2 study of Soft Tissue Sarcoma and Advanced Non-Small-Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 597
- Enrollment target
- 20
- Study locations
NCT00633789 is a Phase 2 study of Soft Tissue Sarcoma and Advanced Non-Small-Cell Lung Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 597 participants, above the 68-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (778% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00633789, a Phase 2 study of Soft Tissue Sarcoma and Advanced Non-Small-Cell Lung Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 597 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib
Conditions Studied
Interventions
- DRUG Placebo
- DRUG brivanib
Study Locations (20)
Other
- Local Institution - Brussels
- Local Institution - Brussels
- Local Institution - Brussels
- Local Institution - Paris
- Local Institution - Paris
- Local Institution - Freiburg im Breisgau
- Local Institution - Halle
- Local Institution - Maastricht
Buenos Aires
- Local Institution - Buenos Aires
- Local Institution - Capital Federal
- Local Institution - Capital Federal
- Local Institution - Capital Federal
Illinois
- University Of Chicago - Chicago
- Northshore Univ. Healthsystem - Evanston
New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Ctr - New York
Maryland
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins - Baltimore
Pennsylvania
- University Of Pennsylvania - Philadelphia
Alberta
- Local Institution - Edmonton
Ontario
- Local Institution - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 597 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633789
The ClinicalTrials.gov registry entry for NCT00633789 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 597 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 68-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (778% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633789 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Buenos Aires, Illinois.
Frequently Asked Questions
What is clinical trial NCT00633789 about?
NCT00633789 is a clinical study titled "Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types". The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether tha...
What is the current status of trial NCT00633789?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 597 participants. The study started on 2008-06. Estimated completion is 2012-12.
What conditions does trial NCT00633789 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Advanced Non-Small-Cell Lung Cancer, Transitional Cell Carcinoma, Gastric/Esophageal Adenocarcinoma, Pancreatic Cancer Including Ampulla of Vater.
What interventions are being tested in trial NCT00633789?
The interventions under investigation include: Placebo (DRUG), brivanib (DRUG).
Who is sponsoring clinical trial NCT00633789?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633789 being conducted?
This trial has 20 study locations across Illinois, Maryland, New York, Pennsylvania, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.